Kouba et al. suggested the clinical usefulness of serum CA-125 levels measurement as a predictor of response to treatment in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder [16]. The gene discussed is MUC16; the disease is bladder transitional cell carcinoma.